Published within
|«
«
|
...
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
Recent events threaten to further erode US sales of Bayer's Cipro franchise as the pharma battles against greater generic competition and limited uptake of follow-up product Cipro XR. As Datamonitor's Amber Gibson explains, novel generic formulations could potentially find opportunities for greater market diversity, even though this may not be associated with increased value...
Published By Datamonitor
|
07 Jul 2004 |
|
CommentWire
|
Chiron and West Pharmaceutical Services have agreed to develop and market a diphtheria and tetanus nasal vaccine using West Pharmaceutical's ChiSys nasal drug delivery technology. The combination would be most relevant for adult booster vaccinations - a market where the needleless delivery method is likely to be well appreciated by both patients and physicians.
Published By Datamonitor
|
25 Mar 2003 |
|
CommentWire
|
The results of a new study show that lung transplant recipients have a lower risk of death following transplant surgery if they use a new inhaled form of the immunosuppressant cyclosporine. Chiron [CHIR] is developing the inhaled drug to capture a share of the valuable transplant patient market, and the novel delivery system may yet find wider application.
Published By Datamonitor
|
28 Apr 2004 |
|
CommentWire
|
On the recommendation of the Data Safety Monitoring Board, Cell Therapeutics has suspended enrollment in testing Xyotax for pre-menopausal, poor performance status (PS2), female advanced non-small cell lung cancer (NSCLC). As Xyotax is targeting such a specific patient cohort, this six-month delay could prove costly, with Cell Therapeutics now heavily relying upon the drug's FDA Fast Track status.
Published By Datamonitor
|
07 Nov 2006 |
|
CommentWire
|
Clinical trials have, so far, shown that Cell Therapeutics' Xyotax may improve lung cancer treatment by reducing chemotherapy side effects and requiring less infusion time. However, the lung cancer market is likely to be crowded with generic and reformulated paclitaxel in the coming years and Cell Therapeutics will need to team up with a larger pharmaceutical company to market Xyotax effectively.
Published By Datamonitor
|
29 Apr 2003 |
|
Expert View
|
The cancer market is set for a boom in low cost drugs, as a significant number of high value cancer drugs are set to lose patent protection over the next decade, triggering a dramatic influx of cheaper generic equivalents. But as patients and generics manufacturers bask in the glow, pharmaceutical companies will be forced to gamble on innovation for fear of being left out in the cold?<BR />
Published By Datamonitor
|
20 Sep 2002 |
|
CommentWire
|
The high level of under-treatment for cancer pain is a result of poor diagnosis, assessment, and treatment by physicians. It is coupled with an unfounded fear of the use of controlled drugs such as opioids. The key to better management of cancer pain is improved educational programs and the development of dedicated pain management teams.<BR />
Published By Datamonitor
|
27 Mar 2003 |
|
CommentWire
|
Bristol-Myers Squibb and Sanofi-Aventis' proposed settlement with generics firm Apotex, designed to end the companies' dispute over Plavix' US patent protection, has been called into question. It appears the deal could contravene an agreement BMS made with US regulators in 2003. Investors will be worried that, if the pact collapses, conflict over the blockbuster drug's key patent could resurface.
Published By Datamonitor
|
12 Jul 2006 |
|
Expert View
|
After a spate of set backs Bristol-Myers Squibb has been forced to make a profit warning. While generic competition has eaten away at sales, the company's pipeline has failed to produce drugs capable of bolstering the waning revenues. So, with no signs of a reprieve, will Bristol-Myers be able to fight off unwelcome suitors or is a take-over in the offing?
Published By Datamonitor
|
26 Apr 2002 |
|
CommentWire
|
More bad news for BMS: US sales are down from $2.7 billion in Q2 2001 to $1.8 billion last quarter. The massive sales push that inflated wholesalers' stocks in Q4 2001 has hit 2002 sales hard; so has generic competition for three key drugs. The most serious concern at this time is whether there is any source for a sales recovery.
Published By Datamonitor
|
25 Jul 2002 |
|
|«
«
|
...
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.